Backed by Amgen’s four decades of biologics expertise, our high-quality biosimilars can potentially offer more affordable treatment options that contribute to the sustainability of our healthcare system and allow for greater investment in new medicines for patients.

With the introduction of biosimilars to mature marketplaces, competition on a level-playing field between biosimilars and with originator biologics can help deliver cost savings for patients and the healthcare system.

Biosimilars entering and competing in the marketplace provides payers with a means to help manage healthcare budgets, and a more sustainable healthcare marketplace for patients, providers, and insurance system payers.

Two of Amgen’s FDA-approved biosimilars were the first oncology therapeutic biosimilars to be made available in the U.S. for providers and patients.

AMGEN'S LEADERSHIP IN BIOSIMILARS IS HELPING TO DEVELOP A MORE SUSTAINABLE HEALTHCARE SYSTEM